Published in Hepatology on April 01, 1991
Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology (2015) 1.65
Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci (1999) 1.34
The genetics of complex cholestatic disorders. Gastroenterology (2013) 1.24
The immunobiology of primary sclerosing cholangitis. Semin Immunopathol (2009) 1.15
Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest (1992) 1.07
Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology (2014) 1.01
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol (2012) 1.00
Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97
Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol (2014) 0.92
Biliary Mucosal Barrier and Microbiome. Viszeralmedizin (2015) 0.89
Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol (2011) 0.87
Development and characterization of a rodent model of immune-mediated cholangitis. Proc Natl Acad Sci U S A (1996) 0.81
Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig Dis Sci (2005) 0.81
Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis. J Crohns Colitis (2015) 0.79
Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res (2015) 0.79
Association between chronic liver and colon inflammation during the development of murine syngeneic graft-versus-host disease. Am J Physiol Gastrointest Liver Physiol (2010) 0.78
Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC). Int J Mol Sci (2016) 0.77
Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther (2014) 0.76
The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. J Hepatol (2016) 0.76
Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol (2017) 0.75
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function. United European Gastroenterol J (2016) 0.75
Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun (1998) 7.86
Experimental models of inflammatory bowel disease. Gastroenterology (1995) 6.28
Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med (1977) 4.93
Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest (1996) 4.59
Persistence of group a streptococcal cell walls related to chronic inflammation of rabbit dermal connective tissue. J Exp Med (1967) 3.15
Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology (1992) 3.04
Biological properties of streptococcal cell-wall particles. 3. Dermonecrotic reaction to cell-wall mucopeptides. J Bacteriol (1966) 2.93
Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem (1999) 2.79
Biological properties of streptococcal cell-wall particles. I. Determinants of the chronic nodular lesion of connective tissue. J Bacteriol (1965) 2.77
Arthropathic properties related to the molecular weight of peptidoglycan-polysaccharide polymers of streptococcal cell walls. Infect Immun (1982) 2.58
Activation of the alternate complement pathway by peptidoglycan from streptococcal cell wall. Infect Immun (1978) 2.57
Degradation of streptococcal cell wall antigens in vivo. J Bacteriol (1967) 2.55
Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol (1999) 2.55
Suppression of the immune response by microorganisms. Bacteriol Rev (1975) 2.53
Association of experimental chronic arthritis with the persistence of group A streptococcal cell walls in the articular tissue. J Bacteriol (1967) 2.47
Relation of rheumatic-like cardiac lesions of the mouse to localization of group A streptococcal cell walls. J Exp Med (1969) 2.38
Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest (2000) 2.27
The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. Am J Physiol Cell Physiol (2000) 2.21
Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology (1998) 2.18
The relation of experimental arthritis to the distribution of streptococcal cell wall fragments. Am J Pathol (1980) 2.15
Radiologic analysis of arthritis in rats after systemic injection of streptococcal cell walls. Arthritis Rheum (1979) 2.03
Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation (1993) 2.03
Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut (2003) 2.02
Cytotoxicity of rat macrophages activated by persistent or biodegradable bacterial cell walls. Infect Immun (1977) 2.00
The gene-protein database of Escherichia coli: edition 5. Electrophoresis (1992) 1.97
The localization of immunoglobulin and immune complexes in lymphoid tissue. Immunology (1970) 1.95
Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun (2001) 1.94
Measurement of bacterial cell wall in tissues by solid-phase radioimmunoassay: correlation of distribution and persistence with experimental arthritis in rats. Infect Immun (1982) 1.94
Arthropathic properties of cell wall polymers from normal flora bacteria. Infect Immun (1986) 1.88
Processing of streptococcal cell walls by rat macrophages and human monocytes in vitro. Infect Immun (1977) 1.86
Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun (1999) 1.85
IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol (1999) 1.83
Evidence for altered regulation of I kappa B alpha degradation in human colonic epithelial cells. J Immunol (1997) 1.80
Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology (2001) 1.77
Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology (1991) 1.72
Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology (1990) 1.59
Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology (1985) 1.57
Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A (1996) 1.56
Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterology (1993) 1.54
Muramic acid detection in mammalian tissues by gas-liquid chromatography-mass spectrometry. Infect Immun (1980) 1.54
Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol (1998) 1.51
Reactivation of streptococcal cell wall-induced arthritis by homologous and heterologous cell wall polymers. Arthritis Rheum (1985) 1.49
Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med (2008) 1.48
Modulation of the susceptibility of inbred and outbred rats to arthritis induced by cell walls of group A streptococci. Infect Immun (1979) 1.47
Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology (1999) 1.47
Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology (1994) 1.45
Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology (2001) 1.43
The future of research in genitourinary radiology: through the looking glass--a view from the Society of Uroradiology. Radiology (1998) 1.41
Effects of streptococcal cell wall fragments on phagocytosis and tissue culture cells. Infect Immun (1970) 1.33
Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. Infect Immun (2000) 1.33
Thyroid carcinoma--biologic behavior and mortality. Postmortem findings in 42 cases, including 27 in which the disease was fatal. Cancer (1966) 1.33
Soluble peptidoglycan-polysaccharide fragments of the bacterial cell wall induce acute inflammation. Infect Immun (1982) 1.33
Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut (1996) 1.31
Increasing mammography utilization: a controlled study. J Natl Cancer Inst (1993) 1.29
Cytokines induce NF-kappaB in activated but not in quiescent rat hepatic stellate cells. Am J Physiol (1998) 1.29
Biological properties of streptococcal cell-wall particles. II. Purification by density gradient column electrophoresis. J Bacteriol (1965) 1.27
The lrp gene product regulates expression of lysU in Escherichia coli K-12. J Bacteriol (1992) 1.25
Cell-mediated immune response during experimental arthritis induced in rats with streptococcal cell walls. Clin Exp Immunol (1980) 1.24
IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol (2000) 1.24
Immunosuppressant from group A streptococci. Science (1968) 1.23
Antibody response to streptococcal cell wall antigens associated with experimental arthritis in rats. Clin Exp Immunol (1980) 1.22
Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am J Physiol (1999) 1.22
Relationship of complement to experimental arthritis induced in rats with streptococcal cell walls. Immunology (1982) 1.21
Systemic uptake and intestinal inflammatory effects of luminal bacterial cell wall polymers in rats with acute colonic injury. Infect Immun (1988) 1.21
Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan-polysaccharide. J Immunol (1988) 1.21
Lipopolysaccharide induces recurrence of arthritis in rat joints previously injured by peptidoglycan-polysaccharide. J Exp Med (1987) 1.21
What constitutes an adequate operation for carcinoma of the thyroid? Arch Surg (1966) 1.21
Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J Infect Dis (2010) 1.19
Treatment of experimental erosive arthritis in rats by injection of the muralytic enzyme mutanolysin. J Exp Med (1984) 1.19
Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab (1983) 1.19
CSPG4 in cancer: multiple roles. Curr Mol Med (2010) 1.15
Experimental periodontitis induced in rats by streptococcal cell wall fragments. J Periodontal Res (1979) 1.14
Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to prevent chronic inflammation in rats. Gastroenterology (1998) 1.14
Measurement of streptococcal cell wall in tissues of rats resistant or susceptible to cell wall-induced chronic erosive arthritis. Infect Immun (1985) 1.11
Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol (1995) 1.11
Probiotics and inflammatory bowel diseases. Am J Gastroenterol (2000) 1.10
Neuronal, non-neuronal and hybrid forms of enolase in brain: structural, immunological and functional comparisons. Brain Res (1978) 1.10
Adjuvant properties of bacterial cell wall mucopeptides. J Immunol (1966) 1.09
Solid carcinoma of the thyroid gland. Analysis of 53 cases. Cancer (1967) 1.08
Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest (1992) 1.07
Measurement of neuron-specific (NSE) and non-neuronal (NNE) isoenzymes of enolase in rat, monkey and human nervous tissue. J Neurochem (1979) 1.07
Antibacterial action of PMN lysosomal cationic proteins resolved by density gradient electrophoresis. Proc Soc Exp Biol Med (1966) 1.07
Edema-producing activity of group A streptococcal polysaccharide and its possible role in the pathogenesis of cell wall-induced polyarthritis. J Exp Med (1983) 1.07
Postoperative recurrence of Crohn's disease: the enemy is within the fecal stream. Gastroenterology (1998) 1.06
Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun (1991) 1.04